Gastroesophageal acid reflux into the airways can trigger asthma attacks. Indeed, citric acid inhalation causes bronchoconstriction in guinea pigs, but the mechanism of this effect has not been fully clarified. We investigated the role of tachykinins, bradykinin, and nitric oxide (NO) on the citric acidinduced bronchoconstriction in anesthetized and artificially ventilated guinea pigs. Citric acid inhalation (2-20 breaths) caused a dose-dependent increase in total pulmonary resistance (R L ). R L value obtained after 10 breaths of citric acid inhalation was not significantly different from the value obtained after 20 breaths (p ϭ 0.22). The effect produced by a half-submaximum dose of citric acid (5 breaths) was halved by the bradykinin B 2 receptor antagonist HOE 140 (0.1 mol и kg 
Gastroesophageal acid reflux is more common in patients with asthma than in the general population, with an estimated prevalence of 34 to 80% (1) . Furthermore, increasing data suggest that gastroesophageal acid reflux may well represent a trigger of bronchoconstriction either by vagal reflex (the "reflex" theory) or microaspiration of refluxed acid gastric contents into the respiratory tract (the "reflux" theory) (1) (2) (3) . The latter theory of microaspiration as a cause of bronchospasm is supported by different evidence (3); for example, reflux of gastric juice into the lower airways during anesthesia has long been known to produce marked bronchoconstriction (4) . The mechanism of such bronchomotor response is, however, unknown. There is evidence that protons can stimulate a subset of primary sensory neurons to release neuropeptides, namely the tachykinins substance P (SP) and neurokinin A (NKA) and the calcitonin gene-related peptide (CGRP) from their peripheral terminals in guinea pigs (5) . Consistent with this finding is the observation that hydrochloric acid-induced airway mucosal protein extravasation in the rat is blocked by pretreatment with capsaicin (6), a drug that at high doses selectively destroys primary sensory neurons (7) . Tachykinins, when released in the guinea pig airways, cause a series of inflammatory responses (8) , including bronchoconstriction. Bronchoconstriction induced by tachykinin release in the guinea pig airways is mediated by activation of NK 2 and, to a lesser degree, of NK 1 receptors (9) .
It has been demonstrated that citric acid-induced coughing and bronchoconstriction in conscious guinea pigs are abolished by pretreatment with capsaicin (10) . Recently, Girard and coworkers (11) have also observed that pretreatment with capsaicin and SR 48968 (12) , a selective NK 2 receptor antagonist, abolished and inhibited, respectively, citric acid-induced airway hyperresponsiveness in guinea pigs. Moreover, it has been found that SR 48968 and the capsaicin antagonist capsazepine (13) reduced bronchoconstriction induced by citric acid inhalation in guinea pigs (14) . A direct action of protons on sensory nerves may be the mechanism by which citric acid causes bronchoconstriction. However, additional possibilities may exist. For instance, plasma extravasation induced by hydrochloric acid instillation in the guinea pig conjunctiva (15) or the increase in blood flow caused by acid back diffusion in the rat stomach (16) are due to sensory nerve stimulation mediated by the release of bradykinin. Bradykinin, a nonapeptide formed from plasma and tissue precursors during inflammation (17) , induces in guinea pigs a variety of inflammatory responses, including bronchoconstriction, mainly by releasing tachykinins from sensory nerve endings (18) . A favorable condition for bradykinin release from its precursor proteins is a low pH of the milieu (17) . However, there is also evidence that bradykinin causes protection of contracted guinea pig airways by releasing nitric oxide (NO) (19) . NO seems to be a predominant mediator of relaxation of the airways by the nonadrenergic-noncholinergic (NANC) neurotransmission (20, 21) . In the present study we postulated that not only tachykinins but also bradykinin and NO are involved in modulating citric acid-induced bronchoconstriction. To that end we investigated the role of tachykinins, bradykinin, and NO on the bronchoconstriction produced by different doses of citric acid in anesthetized and artificially ventilated guinea pigs. Finally, to determine a potential role of the cholinergic pathway in this bronchial response, we also studied the effect of a muscarinic receptor antagonist on citric acid-induced bronchoconstriction in guinea pigs.
METHODS

Animals
Male Hartley guinea pigs (Pampaloni Laboratories, Pisa, Italy), weighing 300-350 g at the time of housing, were used in this study. They were kept in a temperature-controlled environment with standard laboratory food and water freely available.
Measurements of Total Pulmonary Resistance (R L )
Animals were anesthetized with sodium pentobarbital (45 mg и kg Ϫ 1 , intraperitoneally; Antony Product Corp., Arcadia, CA) and then ventilated artificially through a tracheal cannula, using a costant-volume ventilator (model 683; Harvard Apparatus Co., Inc., South Natick, MA) at a frequency of 80 breaths и min Ϫ 1 . The tidal volume was adjusted to maintain normal arterial blood gases as described previously (22) . Airflow was monitored continuously with a pneumotachograph (A. Fleisch, Medical Inc., Richmond, VA) connected to a differential pressure transducer (model DP45; Validyne Engineering Corp., Northridge, CA). A fluid-filled polyethylene catheter was introduced into the esophagus to measure the esophageal pressure as an approximation of pleural pressure. Intratracheal pressure was measured with a polyethylene catheter inserted into a short tube connecting the trachea cannula to the pneumotachograph. The transpulmonary pressure (defined as the pressure difference between the intratracheal and the esophageal pressures) was measured with a differential pressure transducer (model DP7; Validyne Engineering Corp.). Output signals representing transpulmonary pressure and airflow were amplified with an amplifier (model CD19; Validyne Engineering Corp.) and recorded on a polygraph recorder (model 1508 B Visicorder; Honeywell Inc., Denver, CO). R L was calculated as previously described (22) . The right jugular vein and the left carotid artery were cannulated to permit administration of drugs and to withdraw a sample of blood for arterial blood gas measurement, respectively.
Experimental Design
Baseline R L remained stable for at least 2 h, and no significant changes were produced by aerosol administration (2, 5, 10, and 20 breaths) or intravenous injection (1 ml и kg Ϫ 1 ) of saline (0.9% NaCl) (9, 12) , and CP-99,994 (15) used in the study had previously been shown to selectively block bradykinin B 2 , and tachykinin NK 2 and NK 1 receptors, respectively, in guinea pigs in vivo . The dose of atropine used in the study was able to block the bronchoconstriction induced by acetylcholine (0.5 mol и kg Ϫ 1 , intravenous) in guinea pigs (F. L. M. Ricciardolo, personal observation).
To deliver NO synthase inhibitors, we adopted the validated protocol used previously (19) : guinea pigs inhaled 10 breaths of an aero-
. This procedure was repeated every 5 min for 30 min (total, 60 breaths). Five minutes after the last inhalation of the NO synthase inhibitor or the inactive enantiomer a single aerosolized citric acid challenge (five breaths) was given to each animal. In other groups of animals the following pretreatment was used: 10 breaths of an aerosol containing L -arginine ( L -Arg: 3 mM) or D -arginine ( D -Arg: 3 mM) were administered every 5 min for 30 min to L-NMMA-pretreated animals. Five minutes after the last inhalation of L -Arg or the inactive enantiomer, a single aerosolized citric acid challenge (five breaths) was given to each animal. We already reported that administration of the present doses of L -NMMA, D -NMMA, L -Arg, or D -Arg by aerosol do not affect cardiovascular parameters (19) . 
Statistical Analysis
Values in the text and figures are mean Ϯ standard error of the mean (SEM) from at least five experiments. Statistical comparisons were performed using a one-way analysis of variance and Dunnett's test or bilateral unpaired Student t tests, when appropriate. In all cases, a p value less than 0.05 was considered significant.
RESULTS
Dose-Response of Citric Acid-induced Bronchoconstriction
In naive guinea pigs baseline value R L was 0.20 Ϯ 0.02 cm H 2 O/ml/s (n ϭ 6). Aerosolization of 0.9% NaCl (2, 5, 10, or 20 breaths) did not change the baseline value of R L (data not shown). Aerosolized citric acid (2, 5, 10, and 20 breaths) induced a dose-dependent increase in R L (Figure 1) , with the maximum increase in R L (peak) for each dose within 2 min after the end of the inhalation. Two breaths of aerosolized citric acid significantly increased R L above baseline value (obtained by subtracting the baseline R L from the peak increase in R L : 0.19 Ϯ 0.03 cm H 2 O/ml/s; p Ͻ 0.05). Five breaths of aerosolized citric acid caused a twofold increase above baseline value in R L (0.42 Ϯ 0.04 cm H 2 O/ml/s; p Ͻ 0.01) (Figure 1 ). Ten and 20 breaths of aerosolized citric acid increased R L by four-and fivefold above baseline, respectively (p Ͻ 0.01) (Figure 1) . However, R L value obtained after 10 breaths of citric acid inhalation did not differ significantly from the value obtained after 20 breaths (p ϭ 0.22).
Effect of Atropine on Citric Acid-induced Bronchoconstriction
In guinea pigs pretreated with atropine (1.4 mol и kg Ϫ 1 , intravenous, 15 min before the stimulus), the bronchoconstriction induced by 5, 10, and 20 breaths of citric acid was slightly, but not significantly, reduced in comparison to the bronchial response in vehicle-treated guinea pigs (Figure 2 ).
Effect of HOE 140 on Citric Acid-induced Bronchoconstriction
Vehicle of HOE 140 did not significantly change baseline value of R L and did not affect R L values after administration of aerosolized citric acid at the different doses (5, 10, and 20 breaths) compared with the naive group (Figures 1 and 3) . Increases in R L by the three doses of citric acid were reduced by approximately 50% after pretreatment with the bradykinin B 2 receptor antagonist HOE 140 (0.1 mol и kg Ϫ 1 , intravenous, 15 min before the stimulus) ( Figure 3) . 48968, HOE 140, and CP-99,994 Ϫ1 , intravenous, 15 min before the stimulus) tachykinin receptor antagonists partially reduced the L-NMMA-potentiated bronchoconstriction induced by five breaths of aerosolized citric acid (55%, 50%, and 35%, respectively) ( Figure 7) . The combination of HOE 140 (0.1 mol и kg Ϫ1 , intravenous, 15 min before the stimulus) and CP-99,994 (8 mol и kg Ϫ1 , intravenous, 15 min before the stimulus) further decreased, in a statistically significant manner compared with the group of guinea pigs treated with HOE 140 alone (p Ͻ 0.05), the bronchial response to five breaths of citric acid after treatment with L-NMMA (1 mM, 10 breaths every 5 min for 30 min) (Figure 7) .
Effect of SR
In another series of experiments in the presence of the NK 2 tachykinin receptor antagonist (SR 48968, 0.3 mol и kg Ϫ1 , intravenous, 15 min before the stimulus), we studied the effect of adding HOE 140, CP-99,994, or the combination of both bradykinin B 2 and tachykinin NK 1 receptor antagonists on the L-NMMA-potentiated bronchoconstriction induced by five breaths of citric acid: HOE 140 and CP-99,994 alone reduced the bronchoconstriction by 60% and 55% in comparison with the control (Figure 7) . In animals pretreated with HOE 140, CP-99,994, and SR 48968, the bronchoconstriction induced by five breaths of citric acid after L-NMMA (1 mM, 10 breaths every 5 min for 30 min) was blocked ( Figure 7) .
DISCUSSION
In this study we have demonstrated that aerosol administration of citric acid induced a dose-related bronchoconstriction in guinea pigs, an effect that seems to be due completely to the activation of sensory nerves and the release of tachykinins from their peripheral terminals. This conclusion is based on the observation that the increase in RL caused by a half-submaximum dose of citric acid was abolished by a tachykinin NK 2 receptor antagonist and that the combination of antagonists for NK 2 and NK 1 receptors blocked the bronchoconstriction caused by a submaximum and maximum dose of citric acid. Furthermore, our study rules out the potential involvement of another neural component, such as the cholinergic pathway, in citric acid-induced bronchoconstriction in guinea pigs. In fact, the bronchial response to different doses of aerosolized citric acid (5, 10, and 20 breaths) was not affected by atropine.
These findings are consistent with previous data showing that pretreatment with a dose of capsaicin, which desensitized primary sensory neurons, abolished (10, 11) , and that SR 48968 produced a partial inhibition of the bronchoconstriction (14) and of the airway hyperresponsiveness (11) induced by citric acid inhalation in guinea pigs. The partial inhibitory effect of the NK 2 receptor antagonist SR 48968, in comparison with the complete blockade obtained by capsaicin pretreatment, is not surprising. In fact, it has been shown that bronchoconstriction in response to a high dose of capsaicin or NKA in guinea pigs cannot be abolished completely by NK 2 receptor blockade (9) , because in this animal species NK 1 receptors also contribute to tachykinin-mediated bronchoconstriction. In agreement with this notion, the present study shows that the moderate bronchoconstriction evoked by a low dose of citric acid was fully inhibited by SR 48968, whereas addition of CP-99,994 was necessary to produce complete inhibition of bronchoconstriction caused by a high dose of citric acid.
A major finding of the present study is that bradykinin plays a role in the bronchoconstriction induced by citric acid inhalation in guinea pigs. The bradykinin B 2 receptor antagonist HOE 140 reduced by about 50% the increase in RL caused by inhalation of half-submaximum, submaximum, and maximum doses of citric acid. The combination of the tachykinin NK 1 or NK 2 antagonist with the bradykinin B 2 receptor antagonist did not cause any further reduction in citric acid-induced bronchoconstriction. Thus, the hypothesis may be proposed that part of the bronchial response evoked by citric acid inhalation is due to bradykinin formation in the airways, which leads to tachykinin release and NK 2 and NK 1 receptor activation. There is strong evidence that exogenous bradykinin administration, especially if applied locally into the airways, exerts its proinflammatory action by releasing tachykinins from terminals of capsaicin-sensitive primary sensory neurons (25, 26) . It has also been demonstrated that endogenously released bradykinin may cause bronchial responses by activating this neurogenic inflammatory pathway (27) . Particularly relevant for the present study are the findings that the plasma extravasation induced by hydrochloric acid instillation to the guinea pig conjunctiva (15) and the increase in blood flow in the rat stomach caused by acid back diffusion (16) were due to stimulation of sensory neuropeptides release by bradykinin.
The dose of HOE 140 used in the present study has been found to block diverse effects produced by bradykinin administration completely (18, 25) , and this dose of the antagonist caused only a partial inhibition of the tachykinin-mediated increase in RL caused by citric acid. Therefore, it is possible that additional mechanism(s) are involved in citric acid-induced activation of sensory nerves. Protons have been proposed to affect directly the capsaicin-operated channel/receptor (28) . The recently cloned vanilloid cation channel appears to be stimulated by heat and sensitized by exposure to low pH media (29) . The observation that the capsaicin antagonist, capsazepine, was able to inhibit citric acid-induced bronchoconstriction in guinea pigs (14) , supports the hypothesis that at least part of the ability of citric acid to stimulate sensory nerves might be due to a direct activity and/or sensitization of the vanilloid channel by protons liberated by citric acid.
NO seems to be the main mediator of the NANC relaxation within the airways of various mammals, including humans (30, 31) . Recent findings showed that the bronchoconstrictor action of inhaled bradykinin both in guinea pigs (19) and humans (32, 33) is potentiated by the inhibition of the L-Arg-NO synthase pathway. There is also evidence that bronchoconstriction caused by cold air inhalation in guinea pigs, an effect mediated by bradykinin-induced release of tachykinins, is increased following NO synthase inhibition (34) . Pharmacologic manipulations of this effect of cold air by the tachykinin NK 2 and the bradykinin B 2 receptor antagonists suggested that bradykinin was responsible for the simultaneous release of bronchoconstrictor tachykinins and bronchodilator NO (34). Because we observed that bradykinin appears to be involved in citric acid-induced bronchoconstriction, we also examined whether NO release could occur following exposure to citric acid. The observation that stereoselective inhibition of NO synthase caused a potentiation of the bronchoconstriction induced by citric acid inhalation, an effect that was reversed by L-Arg, but not by D-Arg, indicates that endogenous NO is involved prominently in the modulation of citric acid-induced bronchoconstriction. Furthermore, the present results showed the role of tachykinins and kinins in the increased bronchial response to citric acid after NO synthase inhibition. They also suggest that citric acid inhalation causes the release of bronchoconstrictor mediators, the tachykinins, and simultaneously the release of bronchodilator NO. Both tachykinins and NO may be released following B 2 receptor activation (34, 35) . However, there is evidence that tachykinin NK 1 receptors also may have a role in NO release from guinea pig airway epithelium (36) .
Inhalation of acidic substances, including citric acid, acetic acid, and sulfuric acid aerosol, have been shown to induce cough, bronchoconstriction, and increased bronchial responsiveness in patients with asthma (2, 37) . The mechanisms of these effects of acidic solutions in humans is unknown, although activation of neural pathways is likely. The present investigation in guinea pigs shows that different mechanisms and mediators (with opposing functional effects) are involved in acid-induced bronchoconstriction and suggests that if a similar complexity is also present in patients with asthma and gastroesophageal acid reflux into the respiratory tract, the usage of tachykinin and bradykinin antagonists will be a relevant future treatment.
